Grant of Options

RNS Number : 1890X

Kanabo Group PLC

31 December 2021

 

Kanabo Group Plc

("Kanabo" or the "Company")

Grant of Options

Kanabo Group Plc (LSE:KNB), the pan-European medical cannabis company that focuses on developing and commercialising cannabis-derived products for medical patients and wellness CBD consumers announces the grant of options over a total of 3,150,000 shares to certain employees, including General Manager, Michal Ben Moshe, pursuant to their terms of employment. 

Name	No. of Options	Vested options as of today	Option Exercise Price	Vesting Period for non-vested options
Michal Ben Moshe ) PDMR)	2,025,000	506,250	16.5p	Options shall vest in 12 equal tranches every three months over a 3-year period.
Other employees	1,125,000	-	16.5p	Options shall vest over a 4-year period, with 25% vesting at the end of the first 12-months ("the Initial Vesting") and the remaining 75% vesting in 12 equal tranches every three months following the Initial Vesting.

For further information, please visit http://www.kanabogroup.com/ or contact the following:

Kanabo Group Plc
Avihu Tamir, CEO	Via Vox Markets
Peterhouse Capital Ltd
Eran Zucker (Financial Adviser)	Tel: [phone]
Lucy Williams / Charles Goodfellow (Corporate Broker)	Tel: [phone]
Vox Markets (Investor Relations)
Kat Perez	[e-mail]

About Kanabo Group Plc

Kanabo Group Plc is creating a new standard in the medical cannabis industry to improve the well-being of millions of people around the world by providing a better alternative to the smoking of medicinal cannabis flowers. Kanabo, which was the first medicinal cannabis company to IPO on London Stock Exchange, has a focus on the distribution of cannabis-derived products for medical patients and non-THC products for CBD consumers. It has conducted extensive Research & Development to produce high-quality cannabis extract formulas, innovative medical-grade vaporizers, and various non-smoking consumption solutions. Kanabo sells a range of medical cannabis products and wellness CBD products in the Primary Markets, including its VapePod, which delivers a metered dose with every inhalation.

The Notification of Dealing Form provided in accordance with the requirements of the Market Abuse Regulation in relation to the transaction listed above is set out below.

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Michal Ben Moshe
2	Reason for the notification
a)	Position/status	Manager
b)	Initial notification /Amendment	Initial Notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Kanabo Group Plc
b)	LEI	213800XPJFSNWJIYKN52
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Ordinary Shares
	Identification code	GB00BYQCS703
b)	Nature of the transaction	Share Options
c)	Price(s) and volume(s)
			Price(s)	Volume(s)
			16.5p	2,025,000
d)	Aggregated information
	- Aggregated volume	N/A
	- Price	N/A
e)	Date of the transaction	24.10.2021
f)	Place of the transaction	London Stock Exchange

 

END

 

 

DSHDKDBPCBDKCBN